赖斯-比克勒斯角膜营养不良患者经光治疗性角膜切削术或穿透性角膜移植术后的光学相干断层扫描复发特征与治疗
该回顾性介入病例系列纳入17例赖斯-比克勒斯角膜营养不良患者(31眼,1996至2022年共44次手术),评估光治疗性角膜切削术(PTK)或穿透性角膜移植术(PKP)后的复发特征与视力结局。PTK与PKP术后最佳矫正视力均改善,但PTK组显著复发中位时间(27个月)短于PKP组(96个月),上皮下沉积物年增厚在PTK后约14微米、PKP后约7微米、重复PTK后约14微米、角膜植片PTK后约30微米。作者认为PTK可获得优于PKP的视力,上皮下沉积物的浅层分布使重复PTK(包括在角膜同种移植片上)可行。
要点
- PTK与PKP术后最佳矫正视力均较术前改善(P<.001)。
- 显著复发中位时间PTK组27个月,短于PKP组96个月(P<.001)。
- 上皮下沉积物位于上皮与前部基质之间,深度约115微米。
核心结论
- 作者认为,治疗赖斯-比克勒斯角膜营养不良时,PTK术后可获得优于PKP的视力。
- 上皮下沉积物的年增厚可能近似于中央角膜厚度的增加。
- 上皮下沉积物的浅层分布使重复PTK(甚至对同种异体角膜植片行PTK)治疗复发性赖斯-比克勒斯角膜营养不良具有可行性。
研究设计与样本
- 回顾性介入病例系列,纳入17例赖斯-比克勒斯角膜营养不良患者(31眼,包括6只未手术眼和25只手术眼),1996年至2022年间共接受44次手术干预。
- 初始手术方式为PTK或PKP;当最佳矫正视力下降至少2行且浅层角膜混浊增加时判定为显著复发;若患者因显著复发无法忍受视力低下,则考虑重复PTK或对植片行PTK(CG-PTK)。
- 采用眼前节光学相干断层扫描评估复发深度及中央角膜和上皮下沉积物厚度的年增加量。
主要发现
- 平均随访时间12.8±8.5年(范围2.0-25.5年)。
- 平均logMAR最佳矫正视力:初始PTK组13眼从术前1.24±0.48改善至术后0.27±0.09(P<.001);PKP组12眼从1.84±0.69改善至0.40±0.13(P<.001);重复PTK组7眼12次从1.04±0.46改善至0.30±0.07(P<.001);CG-PTK组5眼7次从1.29±0.43改善至0.39±0.11(P=.001)。
- 显著复发中位时间:初始PTK组27个月(95%CI 23.9-30.1),PKP组96个月(95%CI 84.1-107.9),重复PTK组31个月(95%CI 28.8-33.1),CG-PTK组24个月(95%CI 19.8-28.2)(P<.001)。
- 上皮下沉积物位于上皮与前部基质之间,深度约115微米(85-159微米)。
- 上皮下沉积物年增厚:初始PTK后14±2微米,PKP后7±3微米,重复PTK后14±3微米,CG-PTK后30±11微米,未手术眼为4±2微米(P值分别为.002、.515、.002、<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the recurrence characteristics on optical coherence tomography and clinical outcomes after phototherapeutic keratectomy (PTK) or penetrating keratoplasty (PKP) in patients with Reis-Bücklers corneal dystrophy (RBCD). DESIGN: Retrospective interventional case series. METHODS: Seventeen patients with RBCD (31 eyes, including 6 surgery-naïve eyes and 25 surgical eyes) received 44 surgical interventions from 1996 through 2022. PTK or PKP was performed as the initial surgical procedure. Significant recurrence was determined when best spectacle-corrected visual acuity decreased at least 2 lines with increased opacity in the superficial cornea. Repeated PTK or PTK on the corneal graft (CG-PTK) was considered if patients could not endure poor vision due to significant recurrence. Recurrence depth and annual increase in thickness of the central cornea and subepithelial deposits were assessed by anterior segment optical coherence tomography. RESULTS: The mean follow-up time was 12.8 ± 8.5 years (range, 2.0-25.5 years). The mean logMAR best spectacle-corrected visual acuity improved from 1.24 ± 0.48 preoperatively to 0.27 ± 0.09 postoperatively in the initial PTK group (13 eyes, P < .001), from 1.84 ± 0.69 to 0.40 ± 0.13 in the PKP group (12 eyes, P < .001), from 1.04 ± 0.46 to 0.30 ± 0.07 in the repeated PTK group (12 times in 7 eyes, P < .001), and from 1.29 ± 0.43 to 0.39 ± 0.11 in the CG-PTK group (7 times in 5 eyes, P = .001). The median significant recurrence time was 27 months (95% confidence interval 23.9-30.1), 96 months (84.1-107.9), 31 months (28.8-33.1), and 24 months (19.8-28.2), respectively (P < .001). The depth of superficial deposits located between the epithelium and the anterior stroma was approximately 115 µm (85-159 µm). The annual thickening of subepithelial deposits was 14 ± 2 µm after initial PTK, 7 ± 3 µm after PKP, 14 ± 3 µm after repeated PTK, and 30 ± 11 µm after CG-PTK, compared to 4 ± 2 µm in surgery-naïve eyes (P = .002, .515, .002, <.001). The thickness of the central cornea increased by 15 ± 2 µm, 7 ± 2 µm, 15 ± 3 µm, and 31 ± 10 µm per year in the 4 surgery groups, respectively, compared to 5 ± 2 µm in surgery-naïve eyes (P = .001, .469, .001, <.001). CONCLUSIONS: Better visual acuity can be achieved after PTK than PKP for treatment of RBCD. The annual thickening of subepithelial deposits may approximate an increase in central corneal thickness. The superficial distribution of subepithelial deposits makes it feasible to perform repeated PTK, even on the corneal allograft, for recurrent RBCD.
引用
- Li D, Tian LE, Wang X, et al. Recurrence Characteristics on Optical Coherence Tomography and Treatments of Reis-Bücklers Corneal Dystrophy After Phototherapeutic Keratectomy or Penetrating Keratoplasty. Am J Ophthalmol. 2024. PMID: 38735449. doi:10.1016/j.ajo.2024.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。